Lilly Expands In Vivo CAR-T Strategy with Kelonia Acquisition
Eli Lilly to acquire Kelonia Therapeutics in a deal potentially worth up to $7 billion to advance KLN-1010, an in vivo CAR-T therapy for multiple myeloma using the iGPS delivery platform, with the aim of bypassing ex vivo manufacturing and expanding access; closing is expected in the second half of 2026 after customary regulatory approvals.